This is a StreetInsider.com Premium Only Page

Rigel Pharma (RIGL) –

Apr 12, 2024 08:06 AM Form 8-K RIGEL PHARMACEUTICALS For: Apr 11

Apr 10, 2024 05:30 PM Form ARS RIGEL PHARMACEUTICALS For: Dec 31

Apr 10, 2024 04:51 PM Form DEFA14A RIGEL PHARMACEUTICALS

Apr 10, 2024 04:50 PM Form DEF 14A RIGEL PHARMACEUTICALS For: May 22

Apr 10, 2024 04:30 PM Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Apr 4, 2024 08:06 AM Rigel Pharma (RIGL) Announces Publication of Data on REZLIDHIA

Apr 4, 2024 08:05 AM Rigel Announces Publication of Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML in Leukemia & Lymphoma

Mar 29, 2024 05:05 PM Form PRE 14A RIGEL PHARMACEUTICALS For: May 22

Mar 29, 2024 04:09 PM Form 4 RIGEL PHARMACEUTICALS For: Mar 27 Filed by: Rojkjaer Lisa

Mar 29, 2024 04:05 PM Form 3 RIGEL PHARMACEUTICALS For: Mar 27 Filed by: Rojkjaer Lisa

Mar 12, 2024 08:05 AM Rigel Pharma (RIGL) Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Mar 12, 2024 08:05 AM Rigel Pharmaceuticals Announces Appointment of Lisa Rojkjaer, M.D. as Chief Medical Officer

Mar 5, 2024 04:11 PM Form 8-K RIGEL PHARMACEUTICALS For: Mar 05

Mar 5, 2024 04:07 PM Form 10-K RIGEL PHARMACEUTICALS For: Dec 31

Mar 5, 2024 04:02 PM Rigel Pharma (RIGL) Tops Q4 EPS by 2c, Tops on Revenue

Mar 5, 2024 04:01 PM Rigel Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 1, 2024 07:16 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 28 Filed by: Santos David A

Mar 1, 2024 07:16 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 28 Filed by: Schorno Dean L

Mar 1, 2024 07:15 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 28 Filed by: Furey Raymond J.

Mar 1, 2024 07:15 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 28 Filed by: RODRIGUEZ RAUL R

Feb 27, 2024 08:05 AM Rigel Announces Conference Call and Webcast to Report Fourth Quarter and Full Year 2023 Financial Results and Business Update

Feb 26, 2024 08:15 AM Rigel Pharmaceuticals (RIGL) PT Raised to $1.75 at B.Riley

Feb 22, 2024 08:01 AM Form 8-K RIGEL PHARMACEUTICALS For: Feb 22

Feb 22, 2024 07:51 AM Rigel Pharma (RIGL) Acquires U.S. Rights to GAVRETO from Blueprint Medicines (BPMC)

Feb 22, 2024 07:50 AM Rigel Pharmaceuticals Acquires U.S. Rights to GAVRETO®

Feb 14, 2024 02:30 PM Form SC 13G/A RIGEL PHARMACEUTICALS Filed by: ARMISTICE CAPITAL, LLC

Feb 13, 2024 06:12 PM Form SC 13G/A RIGEL PHARMACEUTICALS Filed by: VANGUARD GROUP INC

Feb 9, 2024 12:17 PM Form SC 13G RIGEL PHARMACEUTICALS Filed by: MORGAN STANLEY

Feb 6, 2024 08:19 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Schorno Dean L

Feb 6, 2024 08:19 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Santos David A

Feb 6, 2024 08:18 PM Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: RODRIGUEZ RAUL R

Feb 5, 2024 05:35 PM Form SC 13G/A RIGEL PHARMACEUTICALS Filed by: GOLDMAN SACHS GROUP INC

Feb 2, 2024 09:56 AM Form SC 13G/A RIGEL PHARMACEUTICALS Filed by: Soleus Capital Master Fund, L.P.

Jan 25, 2024 09:18 PM Form 4 RIGEL PHARMACEUTICALS For: Jan 23 Filed by: RODRIGUEZ RAUL R

Jan 25, 2024 09:18 PM Form 4 RIGEL PHARMACEUTICALS For: Jan 23 Filed by: Furey Raymond J.

Jan 25, 2024 09:18 PM Form 4 RIGEL PHARMACEUTICALS For: Jan 23 Filed by: Santos David A

Jan 25, 2024 09:17 PM Form 4 RIGEL PHARMACEUTICALS For: Jan 23 Filed by: Schorno Dean L

Jan 25, 2024 01:50 PM Form SC 13G/A RIGEL PHARMACEUTICALS Filed by: BlackRock Inc.

Jan 10, 2024 08:00 AM Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board

Jan 8, 2024 08:30 AM Form 8-K RIGEL PHARMACEUTICALS For: Jan 08

Jan 8, 2024 08:06 AM Rigel Pharma (RIGL) Provides Business Update

Jan 8, 2024 08:05 AM Rigel Pharmaceuticals Provides Business Update

Jan 5, 2024 04:30 PM Rigel Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

Jan 4, 2024 08:12 AM Rigel Pharma (RIGL) Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

Jan 4, 2024 08:05 AM Rigel Announces Collaboration with CONNECT to Conduct a Phase 2 Trial of Olutasidenib in Glioma

Jan 3, 2024 08:05 AM Rigel to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 8, 2023 08:05 AM Rigel Pharma (RIGL) and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA in AML and Other Cancers

Dec 8, 2023 08:05 AM Rigel Pharmaceuticals and MD Anderson Announce Strategic Alliance to Advance REZLIDHIA® (Olutasidenib) in AML and Other Cancers

Nov 30, 2023 06:05 AM Form 8-K RIGEL PHARMACEUTICALS For: Nov 27

Nov 7, 2023 04:17 PM Form 8-K RIGEL PHARMACEUTICALS For: Nov 07